Biomarker– tag –
-
AI Unlocks CAR T Durability: Single-Cell Models Predict Lasting Remission, Identify Novel Biomarker in B-ALL
bioRxiv USA Overview While CD19-targeted CAR T-cell therapy offers significant hope for B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, approximately half experience relapse within a year. A new study demonstrates that single-cell ... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
UC San Diego Unveils World’s First Fully Integrated Smart Ring for Simultaneous, Continuous Sweat-Based Tracking of Multiple Biomarkers Including Glucose, Ketones, and Vitamin C
UC San Diego Today USA Overview Engineers at UC San Diego have unveiled the world's first fully integrated smart ring capable of simultaneously and continuously tracking multiple biomarkers from sweat, including glucose, ketones, vitamin... -
Xsensio Achieves Key Milestones with ‘Lab-on-Skin®’ Platform, Advancing Continuous Multi-Biomarker Wearable Monitoring for Personalized Healthcare
Propel(x) Switzerland Overview Wearable health monitoring company Xsensio achieved significant milestones in 2026, enhancing sensor integration and device performance through collaborations for its continuous monitoring solutions. The CE... -
bioRxiv: SMART-NeuroDx Achieves Reagent-Free, ML-Driven 4-Analyte Dementia Screening with LoD of 0.087 pg/mL
bioRxiv USA Overview A preprint published on bioRxiv on July 23, 2026, describes SMART-NeuroDx, a reagent-free multianalyte biosensor platform with machine-learning (ML) readout. Aimed at point-of-care dementia screening, this platform a... -
Ultrasensitive ECL Aptasensor Developed for Cardiac Troponin I Detection in Serum, Advancing Myocardial Infarction Diagnosis
ResearchGate International Overview An ultrasensitive electrochemiluminescence (ECL) disposable aptasensor has been developed for the detection of cardiac troponin I (cTnI), a biomarker for myocardial infarction, in blood serum. This apt... -
Romanian Innovator PRION POCT Accelerates Critical Biomarker Detection with 15-Minute Point-of-Care Devices
MTEC Romania Overview PRION POCT, a Romanian company, is advancing medical diagnostics with point-of-care (POCT) devices that provide rapid, quantitative detection of cardiac and other critical biomarkers from whole-blood samples in just... -
Nanotechnology Advances Early Diagnosis and Targeted Therapy for Ovarian Cancer, Significantly Improving Patient Quality of Life
MDPI Switzerland Overview This article discusses rapid advancements in nanotechnology for ovarian cancer management, focusing on early diagnosis and targeted therapy. Nanoparticles, engineered at the 1–100 nm scale, possess unique proper... -
GE HealthCare and Mayo Clinic Collaborate on Personalized Radioligand Therapy for Advanced Prostate Cancer: Launching MI-BET Study
GE HealthCare USA Overview GE HealthCare and Mayo Clinic have initiated the MI-BET study, a collaborative research effort to advance personalized radioligand therapy (RLT) for patients with advanced prostate cancer. This study will integ...
